Sanket Koul

India has moved pregabalin to Schedule H1, tightening prescription and record-keeping norms after states flagged widespread misuse of the nerve pain drug for intoxication

The health ministry has amended clinical trial rules to replace prior approvals for low-risk BA/BE studies with simple online intimations, a move aimed at cutting delays, easing compliance

EU's zero-tariff offer on most chemical and medical exports is set to boost India's pharma, medtech and biosimilars access to European markets

India-EU FTA's focus on mobility could expand choices for Indian students, making Europe a more deliberate study destination even as the US remains key amid uncertainty over visa policies

Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption

In a gazette notification dated January 23, the Union health ministry proposed adding a new clause under Rule 95 of the Drugs Rules, 1945

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

Developer says Q3 sales dropped due to Dahlias pause, no new launches

Realty major states gross zero debt on high net cash position

Move comes just months before nivolumab patent expiry in India on May 2, 2026

Ahead of Budget 2026, realtors seek higher home loan tax deductions, a wider affordable housing definition, and dispute-resolution reforms to revive housing demand

CDSCO has flagged seven drug batches as spurious and listed 167 others as not of standard quality in its December 2025 surveillance, covering common medicines for BP, pain and allergies

The health ministry has amended the NDCT Rules to cut approval timelines for new drug trials and testing by half, aiming to speed up innovation while easing regulatory processes for most applications

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Elan Group awards an Rs 840 crore construction contract to Tata Projects for its ultra-luxury residential project 'Elan-The Statement' in Sector 49, Gurugram

Units priced ₹1 crore and above increase market share to 63% of total units sold in 2025

JB Pharma reports a 22% rise in Q3 FY26 profit as strong growth in domestic and international formulations offsets flat CDMO revenues

With ₹86,588 crore in projects cleared in 2025, Gurugram cements its place as India's hottest real estate hub-spanning premium homes, IT parks and mass housing

Revised criteria for reserved categories; doctor bodies criticise the move

Elie Saab to open first retail store this year